Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FERMT2 | Q96AC1 | 4/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | CCR1 | P32246 | 1/20 | 0.72 |
| ▸ | CDK1 | P06493 | 1/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30817040 | 0.92 | FERMT2 (1.00) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL4278808 | 0.92 | FERMT2 (1.00) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL15483264 | 0.92 | FERMT2 (0.76) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL29578261 | 0.92 | FERMT2 (0.76) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL30817056 | 0.91 | FERMT2 (0.93) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| Hydrochloric Acid SCHEMBL22616749 | 0.90 | FERMT2 (0.74) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| Hydrochloric Acid SCHEMBL13737549 | 0.90 | FERMT2 (0.74) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL15483265 | 0.90 | FERMT2 (0.74) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL14872092 | 0.90 | FERMT2 (0.90) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL15476529 | 0.89 | KDM4E (0.85) | FERMT2KDM4ELMNAHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014786-A1 | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation | RAUT RAJEEV | 2006-01-19 | — | — | US | claimed |
| EP-0656353-B1 | Aminochinoline derivates useful in the treatment of malaria | HOFFMANN LA ROCHE (CH) | 1998-06-03 | — | — | EP | claimed |
| EP-0656353-A1 | Aminochinoline derivates useful in the treatment of malaria | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-07 | — | — | EP | claimed |
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2023-12-28 | — | — | US | disclosed |
| US-9829481-B2 | Senescence tracers | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2017-11-28 | — | — | US | disclosed |
| US-9829481-B2 | Senescence tracers | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2017-11-28 | — | — | US | disclosed |
| US-20150231237-A1 | METHODS AND PRODUCTS FOR TREATING PROLIFERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-08-20 | — | — | US | disclosed |
| US-9073985-B2 | Methods and products for treating proliferative diseases | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150168374-A1 | SENESCENCE TRACERS | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20150168374-A1 | SENESCENCE TRACERS | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2015-06-18 | — | — | US | disclosed |
| WO-2014032737-A1 | SENESCENCE TRACERS | EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET (DE) | 2014-03-06 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20060241139-A1 | Treatment of DNA damage related disorders | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2006-10-26 | — | — | US | disclosed |
| US-7084157-B2 | Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation | RAUT RAJEEV | 2006-08-01 | — | — | US | disclosed |
| US-20060014786-A1 | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation | RAUT RAJEEV | 2006-01-19 | — | — | US | disclosed |
| US-20050124653-A1 | Treatment of dna damage related disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-09 | — | — | US | disclosed |
| US-20050032834-A1 | Treatment of DNA damage related disorders | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2005-02-10 | — | — | US | disclosed |
| US-20050014785-A1 | Treatment of radiation disorders | PERLEGEN SCIENCES, INC. (US) | 2005-01-20 | — | — | US | disclosed |
| EP-0656353-B1 | Aminochinoline derivates useful in the treatment of malaria | HOFFMANN LA ROCHE (CH) | 1998-06-03 | — | — | EP | disclosed |
| EP-0656353-A1 | Aminochinoline derivates useful in the treatment of malaria | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014785-A1 | Treatment of radiation disorders | XRCC5, XRCC6, QTRT1 | FERMT2 1949/4885KDM4E 595/4885LMNA 198/4885 |
| US-20050124653-A1 | Treatment of dna damage related disorders | ERCC1, ERCC5, ERCC2 | FERMT2 2890/4885KDM4E 1059/4885LMNA 210/4885 |
| US-20060014786-A1 | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation | AQP4, IL5, CCL11 | FERMT2 3867/4885KDM4E 2475/4885LMNA 4425/4885 |
| US-20050032834-A1 | Treatment of DNA damage related disorders | BRCA1, ERCC4, POLN | FERMT2 3430/4885KDM4E 4109/4885LMNA 100/4885 |
| US-20150168374-A1 | SENESCENCE TRACERS | AGER, FUCA1, FUCA2 | FERMT2 2353/4885KDM4E 2437/4885LMNA 576/4885 |
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | ERCC4, LIG4, LIG3 | FERMT2 4086/4885KDM4E 1405/4885LMNA 412/4885 |
| US-20150231237-A1 | METHODS AND PRODUCTS FOR TREATING PROLIFERATIVE DISEASES | BECN1, G6PD, VHL | FERMT2 4031/4885KDM4E 1236/4885LMNA 3405/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | FERMT2 2880/4885KDM4E 3242/4885LMNA 415/4885 |
| US-20060241139-A1 | Treatment of DNA damage related disorders | BRCA1, ERCC4, POLN | FERMT2 3430/4885KDM4E 4109/4885LMNA 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.